---
document_datetime: 2025-04-15 14:50:39
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/prometax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: prometax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5597422
conversion_datetime: 2025-12-28 09:15:35.929761
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Prometax

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - | 14/04/2025                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000263657                      | Update of the product information to align the ADRs listed in sections '4 Possible side effects' of the package leaflet with section 4.8 of the SmPC and to introduce an updated image for Prometax transdermal patch (EU/1/98/092/019-042) under 'Where to apply your Prometax transdermal patch' in section '3. How to use Prometax' of the package leaflet. Additionally, the MAH took the opportunity to introduce minor editorial amendments to the package leaflet of some of the translations.   |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000262295 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                       | 03/04/2025 | N/A |
| Variation type IB / EMA/VR/0000248521 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the                                                                                                                                                                                               | 17/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| specification with its corresponding test method - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|